Within the synthesis a fivefold excess of amino acid over resin reactive groups (100 μmol, 200 μL of 0.5 M solution) was used for each coupling. In situ activation and coupling was carried out for 45 min with a mixture of HBTU-HOBt (100 μmol, 200 μL of a 0.5 M solution) and NMM (100 μmol, 200 μL of 0.5 M solution). The peptide was washed with DMF (3 x 1 mL) between each deprotection and coupling step. A typical cycle consisted of Fmoc deprotection, DMF wash, coupling and a further DMF wash. N-α-Fmoc protection at the final residue was removed at the end of the synthesis under usual conditions. Following synthesis, the peptidyl resin was removed from the synthesizer, washed several times (3 x 2 mL DMF, 3 x 2 mL DCM, 3 x 2 mL methanol, 3 x 2 mL diethylether) and dried in a desiccator over silica gel, unless otherwise stated. For deprotection and cleavage from the resin, a standard 'deprotection mixture' of TFA-H 2 O-DTT-TIS (94 : 2.5 : 2.5 : 1) was used in all reactions (1.5 ml of mixture to 20 µmol of dry peptide bound resin), unless otherwise stated. After cleavage, crude mixtures were precipitated using ice cold TBME, centrifuged at 4000 rpm for 10 minutes at 4 o C, supernatants were discarded and the remaining peptides were washed with a fresh aliquot of TBME. The process was repeated. Crudes were subsequently dried in a desiccator over silica gel after which the solids were dissolved in a water methanol mixture and purified by RP-LCMS. Pure fractions were combined and lyophilized.
NODA-dLVT
After peptide synthesis, the resin was retrieved, washed and swelled in DMF for 1 h. Solvent was removed and a solution of 2% v/v hydrazine monohydrate in DMF was added. The mixture was agitated for 1 h, the deprotection mixture removed, and the resin washed. This process was repeated and resin bound peptide was used directly for conjugation. For this, HATU (44 mg, 115 µmol) in DMF (200 µL) was added dropwise to a mixture of NODA-MPAA (61 mg, 120 µmol), 2 and DIPEA (21 µL, 120 µmol) in DMF (400 µL). The mixture was agitated for 5 min then added to a DMF slurry of DIPEA (21 µL, 120 µmol) and resin bound dLVT (40 µmol) with the free lysine residue. The mixture was agitated for a further 2.5 h, after which the solution was removed by suction and washed. Resin was subsequently dried in a desiccator overnight then deprotected and cleaved using a mixture of TFA/DTT/H 2 O/TIS (91 : 3 : 3 : 3) for 3 h. Crude mixture was precipitated, centrifuged and dried in a dessicator, after which time the solid was dissolved and purified by RP-LCMS. Following lypolization a white solid was afforded (16 mg, 29%). Cyclisation was achieved using phosphate buffer (0.01 M, pH 7.5), at room temperature with 15% v/v DMSO (at a peptide concentration of 1 mg/ml) for 48 h. The peptide was purified by preparative RP-LCMS, affording NODA-dLVT as a white solid after lyophilisation (77%).
AlF-NODA-dLVT
The synthesis of AlF-NODA-dLVT followed a similar protocol to one reported elsewhere. 3 Briefly, NODA-dLVT (2 mg, 1.45 µmol) was dissolved in 2 mM sodium acetate buffer (110 µl, pH 4.4) and ethanol (55 µL), and treated with AlF 3 .3H 2 O (1.1 mg, 7.25 µmol). The pH was adjusted to 4.8 and the reaction mixture was refluxed for 90 min. The mixture was cooled, the crude diluted five-fold and purified by preparative RP-LCMS to yield cold tracer as a white solid after lyophilization (1.8 mg, 87%).
Reduced AlF-NODA-dLVT
AlF-NODA-dLVT (0.5 mg, 0.35 µmol) was dissolved in ammonium bicarbonate (0.1 M, pH 8) at a concentration of 1 mg/ml, and dithiothreitol (0.54 mg, 3.5 µmol) was added. The mixture was left to stand at room temperature for 3 h, then purified by LCMS affording reduced peptide after lyophilisation (0.4 mg, 80%).
Synthesis of OT and peptide analogues
Synthesis of reduced open chain peptides followed the general procedure. Once completed, peptides were cleaved using the usual deprotection mixture and work up. Peptides were dissolved in a water methanol mixture and purified by RP-LCMS. Oxidation, when required, was performed in air with 0.1 M ammonium hydrogen carbonate buffer (peptide concentration of 0.1 mg/ml) for up to 3 days, after which the solution was concentrated, then lyophilised to yield pure peptides.
NODA-dLVT labelling with Al 18 F
Care was taken to ensure reactants were prepared in metal free conditions. A stock solution of NODA-dLVT in water was made. Aliquots (72 nmol) were removed and placed in eppendorfs for lyophilization. For the preparation of buffer solutions, any pH adjustment made used metal free glacial acetic acid.
Preparation of Na 18 F
In a typical procedure a QMA cartridge was washed with 0.5 M sodium acetate buffer (10 ml, pH 8.4), followed by deionized water (10 ml), as described previously. 4 [ 18 F]fluoride solution (6-10 mL; 1 GBq) was loaded onto the cartridge, washed with water (2 ml) and Na 18 F was eluted with 20% saline solution into 100 µL fractions. The fraction containing the highest activity (790 MBq) was subsequently used for radiolabelling.
Synthesis of [ 18 F]AlF-NODA-dLVT
To eluted Na 18 F, 2 mM AlCl 3 (10 µL, 20 nmol) in 0.1 M sodium acetate buffer, pH 4.1, was added. The solution was added to a mixture of NODA-dLVT (72 nmol) in 0.5 M NaOAc buffer (10 µL; pH 4.0). The reaction mixture was incubated at 100 o C for 15 min and purified by manual RP-HPLC, affording isolated tracer.
Radiolabelling time: The length of reaction was studied using a molar ratio of 0.6:1 aluminium chloride to peptide with 20% saline (n=3). 18 F yields were not improved through extending the reaction time past 15 min: at 5 min, 18 F yield was 40 ± 8% and at 15 min the labelling efficiency was 84 ± 2%. After 30 min 18 F yields remained at 84 ± 3%. 
Autoradiography Procedure
Tissue was thawed to room temperature, dried then washed with ice cold buffer (50 mM Tris, 
i.n. administration
A 0.3 mL insulin syringe, containing a 29-gauge needle, was fitted with a PE10 cannula (15 mm). The cannula was fitted so that it covered approximately 3 mm of the needle tip.
Radioligand was added to the syringe and the activity measured before and after administration to calculate the injected dose (ID). Anesthesia was induced using a mixture of 5% isoflurane and oxygen (Animalcare, UK) at a flow rate of 1 L/min and maintained at 2.5% isoflurane.
Once unresponsive, the rat was held in an almost vertical position and radioactivity was administered through one nare at the back of the nasal cavity.
Biodistribution
Rats were sacrificed by removal of the heart under isoflurane anaesthesia at 10 min following 
